Thu, 03 Nov 2016 08:00:00 EDTA laboratory automation system that is capable of carrying out clinical chemistry assays, immunoassays, amplification of nucleic acid assays, and any combination of the foregoing, said laboratory automation system employing at least one of micro-well plates and deep multi-well plates as reaction vessels. The use of micro-well plates as reaction vessels enables the laboratory automation system to assume a variety of arrangements, i.e., the laboratory automation system can comprise a variety of functional modules that can be arranged in various ways. In order to effectively carry out immunoassays by means of micro-well plates, a technique known as inverse magnetic particle processing can be used to transfer the product(s) of immunoassays from one micro-well of a micro-well plate to another.
Thu, 03 Nov 2016 08:00:00 EDTA three dimensional (3-D) model comprising a scaffold and autologous skin cells, the invention also provides methods of predicting immunogenicity and hypersensitivity or allergic or adverse immune reactions to potential therapeutic compounds, biologies, cosmetics and chemical sensitizers using the 3-D model of skin cells. The methods provide an in vitro assay employing autologous blood derived cells in the 3-D skin equivalent model and is of particular utility in the identification and prediction of skin sensitizers and in particular agents that may cause allergic contact dermatitis. The assay of the present invention provides inter alia methods of screening library compounds for sensitizing activity, identifying optimal therapeutics, especially but not exclusively, monoclonal antibodies and kits therefor.
Thu, 03 Nov 2016 08:00:00 EDTDry, pelletized reagents are described which rapidly reconstitute into active reagent solutions when contacted with an appropriate liquid sample or other appropriate solution, including heterogeneous reagent pellets made from two or more separate reagent solutions in such manner that components in the separate reagent solutions which will normally react with each other in solution do not substantially react. Also described are reagent dispenser packages and assay devices containing dry pelletized reagents.
Thu, 03 Nov 2016 08:00:00 EDTThis invention relates to a simple end point assay for detection of transient intracellular Ca2+ with broad applicability to many Ca2+ channel proteins comprising, Generation of expression constructs for the fusion proteins having the Ca2+/calmodulin dependent protein kinase II (CaMKII) phosphorylation sites of NR2A or NR2B subunits of N-methyl-D-aspartate receptor (NMDAR) or the voltage gated potassium channel of Drosophila (Eag) or any protein sequence which binds to the T-site of CaMKII similar to NR2B, conjugated to mitochondrial localizing signal sequence, or mutants of these sequences as described herein. Generation of mammalian expression constructs of α-CaMK11 as a chimera with green fluorescent protein (GFP-α-CaMKII) or its mutants as described herein. Site-Directed mutagenesis, Transfection, Ca2+ stimulation, imaging and quantification of the number of cells with Ca2+-dependent signal, wherein, NMDA receptor activity assay, TRPVI receptor activity assay, GluR4 receptor activity assay are performed to detect the activity of Ca2+ channel proteins.
Thu, 03 Nov 2016 08:00:00 EDTThe invention provides diagnostic tests to distinguish between different pre-symptomatic neurodegenerative diseases.
Thu, 03 Nov 2016 08:00:00 EDTMethods to estimate safety and/or efficacy of therapeutic drugs, which include portable devices for anti-drug antibody (ADA) testing and databases containing anonymized data from human and/or animal models and related analyses, are provided. These methods and compositions can be used in various applications, including but not restricted to the following: uniform testing of patients for ADA; selection of therapeutic drug for patient treatment; evaluation of the need to change therapeutic drug or to apply tolerance regimens; selection of patients for clinical trials; comparison of therapeutic drugs marketed for a given disease and also gene therapy; scientific guidance for discovering and/or developing therapeutic drugs; postmarketing surveillance of therapeutic drugs.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds comprise hydroxypyridinonyl moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability.
Thu, 03 Nov 2016 08:00:00 EDTAspects of the disclosure relate to improved methods and systems for active surveillance of subject having non-aggressive prostate cancer.
Thu, 03 Nov 2016 08:00:00 EDTMonoclonal and polyclonal antibodies that bind hamster phospholipase B-like 2 are provided. Also provided are methods for detecting and quantifying hamster phospholipase B-like 2, for example, in recombinant polypeptide preparations, as well as kits for carrying out such methods. Methods of screening or selecting host cell lines or recombinant polypeptide-expressing cell lines that express low levels of hamster phospholipase B-like 2 are also provided.
Thu, 03 Nov 2016 08:00:00 EDTThe object is to provide a lysis method, lysis treatment solution, detection method using an immunochromatographic device, and detection kit comprising an immunochromatographic device for detecting whether causative bacteria of mastitis are coliform bacteria or not by using milk of a livestock animal. There is provided a method for lysing coliform bacteria, which comprises the step of mixing a lysis agent containing a lytic enzyme, and at least one kind of anionic surfactant, and preferably further containing at least one kind of nonionic surfactant, with milk obtained form a livestock animal to lyse coliform bacteria existing in the milk. The lytic enzyme is preferably lysozyme.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention fitted in the medical-clinical sector, shows a method for monitoring the ingestion of gluten by measuring protein/gluten peptides present in fecal samples with antibodies against immunogenic peptides resistant to gastrointestinal digestion. The presence or absence of these immunogenic peptides is controlled by immunological assays based on antibodies reactive against immunogenic gluten peptides that are resistant to proteolysis. These assays may be quantitative techniques ELISAs, or qualitative as rapid immunochromatographic assays, immunoblots, etc. These measures may also be applied to verify compliance with the gluten-free diet, to improve diagnosis in cases of refractory or severe symptoms of celiac disease in which a gluten-free diet is supposedly being respected, or to clinical research on the effectiveness of enzymatic therapies related with prolamin detoxification.
Thu, 03 Nov 2016 08:00:00 EDTThe invention provides an apparatus and methods for the electrochemical detection and/or quantitation of an analyte in a sample, wherein the device comprises a substrate and a detector, wherein the substrate comprises a labeled binding agent, wherein the label is an enteric material particle that encapsulates a ferrocene methanol redox species.
Thu, 03 Nov 2016 08:00:00 EDTProcesses and compositions are described for preparing new, colloidally stable, coated nanomagnetic particles useful for both in-vitro and in-vivo biomedical applications, including cell targeting and capturing cells, microorganisms, and cellular organelles or entities such as exosomes. These nanomagnetic particles can also be used as imaging contrast agents due to their small size and high magnetic moment. The nanomagnetic particles include a series of sequentially added, stabilizing surface coatings rendered onto nano-sized magnetic crystal clusters (e.g., magnetite particles) to impart colloidal stability in complex biological samples with minimal leaching of the coating materials, high binding capacity, and low non-specific binding. Another benefit of this invention is the ability to utilize both external and internal magnetic field-generating separation devices to effect separation of the magnetic nanoparticles.
Thu, 03 Nov 2016 08:00:00 EDTIn a method of detecting a test substance, a test substance is detected using a sample analysis cartridge supplied with a sample. The sample analysis cartridge includes: a passage part having a gas-phase space; and liquid containers communicating with the passage part through openings. The liquid containers include: a first liquid container containing a first liquid containing magnetic particles; and a second liquid container containing a second liquid containing a labeled substance 42. The magnetic particles are sequentially transported to the liquid containers through the gas-phase space in the passage part. Thus, the magnetic particles carry a complex of the test substance and the labeled substance. The test substance is detected based on the labeled substance in the complex.
Thu, 03 Nov 2016 08:00:00 EDTA subtractive corrective assay device and methodology, whereby ail required binding and label detection reagents are initially located within the detection zone. Application of a magnetic field is used to selectively remove bound label from the detection zone by means of paramagnetic particles. The relationship between measured label concentration before and after the application of a magnetic field within the detection zone is used to accurately measure analyte concentration within the sample.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides compositions exhibiting in vivo activity of fibrin in an in vitro setting, in vitro assays comprising such compositions, methods of producing such compositions, and methods of using such compositions and assays. The compositions of the invention include molecules with the biochemical properties of 1) high affinity binding to fibrin receptors and 2) activation of cell-signaling systems comparable to that observed in vivo by fibrin. The fibrin compositions of the invention are compatible both in biochemical assays and cell-based assays, and thus useful for in vitro assays for screening of test agents that modulate cell activation and/or signaling pathways mediated by fibrin or associated with fibrin activity.
Thu, 03 Nov 2016 08:00:00 EDTA method and device for analyzing a hematologic sample centrifuged within a capillary tube is provided. The device includes a tube holder, a sample imaging device, a processor, and a sample data display. The sample imaging device is operable to create a digital image of the sample within a region of the tube. The region is defined by substantially all of the radial width and axial length of the sample residing within the internal cavity of the tube in the region where the float resides after centrifugation. The sample imaging device is operable to produce signals representative of the image. The processor is adapted to produce information relating to bands of interest within the image based on the signals from the sample imaging device. The sample data display is adapted to display the results therefrom and/or a digital image of the sample within the region.
Thu, 03 Nov 2016 08:00:00 EDTThe invention relates to containers or bags for chromatographic media and methods of packing chromatography columns using such containers. The bags may be used for storing and/or transporting chromatographic media and can be inserted directly into the chamber of a chromatography column in readiness for use.
Thu, 03 Nov 2016 08:00:00 EDTMethod for determining, in vitro, the cell aggressiveness grade of cancer cells or for detecting cancer stem cells in a cell sample originating from a solid tissue suspected of being cancerous, includes: a) dissociating the cell cluster constituting the sample into a suspension of whole and viable isolated cells, b) macroscopically sorting the cells to obtain homogeneous subpopulations, c) calibrating at least one microwave electromagnetic sensor resonating at its own resonance frequency, d) presenting the dissociated and sorted cells to the calibrated sensor, e) interrogating the sensor and determining its new resonance frequency having received the cells, f) calculating the variation in overall dielectric permittivity of the cells according to the variation in working frequency, which constitutes the electromagnetic signature of the cells. The macroscopic sorting is without prior labelling and is based on the intrinsic properties of the cells. A kit for implementing the method is also described.
Thu, 03 Nov 2016 08:00:00 EDTA disposable, self-contained tobacco smoke detector, comprising a sensor incorporated with a reagent capable of undergoing one or more chemical reactions by interacting with one or more compounds unique to tobacco smoke. The smoking detector further comprises an indicator coupled to the sensor for visually indicating the occurrence of at least one chemical reaction by producing a detectable change in color, indicating exposure to tobacco smoke, thereby providing visual evidence of smoking.
Thu, 03 Nov 2016 08:00:00 EDTProvided are inexpensive devices and methods for obtaining emission or scattering spectra of multiple particles simultaneously and for characterizing the particles based on their emission or scattering spectra. The disclosed devices and methods are useful for analyzing multiple particles to determine one or more characteristics of the particles, such as size, type, elastic scattering, fluorescence and/or Raman characteristics, for distinguishing between biological and non-biological particles, and for biomedical assaying applications. Laboratory or research grade spectroscopic devices are described. Smartphone-based spectroscopic devices are also described, where various components of a smartphone are used for data collection and analysis purposes.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides systems and methods for analyzing the excitation spectra of fluorescent particles in a flowing stream. The system uses a white light laser and color separation optics to provide a spatially-distributed, continuous color-spectrum excitation light system that is used to illuminate a region of a flowing stream. A particle that passes through the detection region traverses the full dispersed spectrum of excitation light, and the fluorescence emissions from the particle are continuously measured as it passes through the detection region. The measured fluorescence emissions at each wavelength of excitation light, which changes through full spectrum of the excitation light as the particle passes through the detection region, provides the excitation spectrum of the particle.
Thu, 03 Nov 2016 08:00:00 EDTA particle analysis apparatus includes: an acquisition unit that acquires a plurality of images each captured at a different time in each of which a particle moving in a predetermined direction in a medium is imaged; and a determination unit that determines, based on a movement amount of a particle due to Brownian motion in the medium, whether or not an image of a first particle included in an image captured at a first time of the plurality of images acquired by the acquisition unit and an image of a second particle included in an image captured at a second time which is different from the first time of the plurality of images acquired by the acquisition unit are images indicating the same particle.
Thu, 03 Nov 2016 08:00:00 EDTA device consisting activated microfibers, such as glass and cellulose, comprising the 3D network, packed in small volumes, traps and concentrates the bacteria from trace contaminated liquids rapidly. It functions for concentrating and rapid detection of microbes in
Thu, 03 Nov 2016 08:00:00 EDTA method and device performing the method for estimation of cell count, such as sperm cell count, is disclosed. The device may be a kit including a cartridge configured to hold fluid, such as seminal fluid, and an instrument configured to centrifuge the cartridge. The cartridge and instrument are configured such that, during operation or centrifugation, they are securely attached to each other. The cartridge has a component with a defined cross-sectional volume. The defined cross-sectional volume is used to mark the component with markings, allowing a user of the device to read the markings and estimate cell volume and, thus, concentration. Various embodiments of the device are disclosed.
Thu, 03 Nov 2016 08:00:00 EDTDisclosed are methods, compositions and kits for the isolation of exosomes from biological fluids and tissues. Volume-excluding polymers are used to precipitate exosomes from biological samples thereby allowing exosome isolation by low-speed (benchtop) centrifugation or filtration. Further fractionation of exosomes after precipitation is also described.
Thu, 03 Nov 2016 08:00:00 EDTA micro flow device (11, 71) for separating or isolating cells from a bodily fluid or other liquid sample uses a flow path where straight-line flow is interrupted by a pattern of transverse posts (23, 81). The posts are spaced across the width of an expanded collection chamber region (17, 75) in the flow path, extending between the upper and lower surfaces thereof; they have rectilinear surfaces, being curved in cross-sections, e.g. circular or tear-drop shaped, and are randomly arranged so as to disrupt streamlined flow. The device is oriented so that its lower surface is aligned at about 45° to the horizontal. Sequestering agents, such as Abs, which are attached to surfaces of the collection region via a hydrophilic coating, preferably a permeable hydrogel containing isocyanate moieties, are highly effective in capturing cells or other targeted biomolecules while the remainder of the liquid sample exits horizontally.
Thu, 03 Nov 2016 08:00:00 EDTA valve disposed at a flow path includes: a substrate having a first surface in which a hole having an opening section is formed; and a diaphragm member fixed to at least part of a wall surface of the hole and in which at least a central portion has a thin film shape, wherein a flow of a fluid in the flow path is controlled by deforming the diaphragm member.
Thu, 03 Nov 2016 08:00:00 EDTA method is provided for loading or reloading a decomposition unit of an SCR system, the SCR system being mounted on board a vehicle and including a filler pipe in communication with the decomposition unit. The method is such that at least one capsule containing at least one protein component adapted to decompose ammonia precursor is introduced through the filler pipe and is then guided through the filler pipe towards the decomposition unit.
Thu, 03 Nov 2016 08:00:00 EDTDisclosed herein are materials and methods for achieving sequence-specific organism detection and/or phenotype(s) using sequence-specific oligonucleotides. Also disclosed are related kits, cultures, and cells for detecting and/or phenotyping microorganisms in a sequence-specific manner.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to methods for the identification of anti-HIV miRNAs and anti-HIV pharmaceutical compounds using high-throughput screening methods, comprising: transfecting reporter cells with a panel of miRNAs, infecting the reporter cells with HIV, screening the cells to identify miRNAs that modulate HIV infection and identifying the specific pathways, nucleic acids and/or polypeptides that are targeted by the miRNAs. The invention further provides for the identification and screening of anti-HIV pharmaceutical compounds having known activity against the specific pathways, nucleic acids and/or polypeptides that are targeted by the miRNAs for efficacy in the treatment of HIV. The invention also provides for the use of miRNA mimics, miRNA inhibitors and pharmaceutical compounds (including oncology drugs and kinase inhibitors) in the treatment and/or prevention of HIV infection.
Thu, 03 Nov 2016 08:00:00 EDTDescribed herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides compositions and methods for research, diagnostic, drug screening, and therapeutic applications related to paroxysmal dystonic choreoathetosis and related conditions. In particular, the present invention provides mutations in the myofibrillogenesis regulator 1 (MR-1) gene associated with such conditions.
Thu, 03 Nov 2016 08:00:00 EDTSystems and methods for detecting at least two genomic alleles associated with corneal dystrophy in a sample from a human subject are disclosed in which cells (e.g., epithelial) of the subject are adhered to a tip of a substrate. The tip of the substrate is agitated in a lysis solution that lyses cells adhered to the substrate. The substrate is removed from the lysis solution upon completion of this agitation. The resulting lysis solution is incubated and then genomic DNA from the lysis solution is isolated to form a gDNA solution. From this, identity of at least two nucleotides present in the human TGFβI gene is determined using at least two oligonucleotide primer pairs and the gDNA solution. These at least two nucleotides are located at respective independent positions of the TGFβI gene corresponding to respective independent single nucleotide polymorphisms (SNPs) associated with corneal dystrophy.
Thu, 03 Nov 2016 08:00:00 EDTReal time redox sequencing methods, devices, and systems are described. Arrays of redox devices comprising one or two electrodes are used to provide sequence information about a template nucleic acid in a polymerase-template complex bound proximate to the electrode(s). A sequencing reaction mixture comprising nucleotide analogs comprising redox labels is introduced to the array of redox devices under conditions of polymerase mediated nucleic acid synthesis. The time sequence of incorporation of nucleotide analogs is determined by electrochemically identifying the redox labels of the nucleotide analogs that are incorporated into the growing strand.
Thu, 03 Nov 2016 08:00:00 EDTProvided are methods of depleting a target nucleic acid in a sample. The methods include contacting a target nucleic acid with two or more polymers that specifically hybridize to the target nucleic acid, and cleaving the hybridized regions of the target nucleic acid to deplete the target nucleic acid in the sample. Kits for practicing the subject methods are also provided.
Thu, 03 Nov 2016 08:00:00 EDTA method including contacting a tissue or cellular sample with a reagent including an evaporation reducing agent(s) having the general formula X1—R—X2, wherein R is an alkyl, alkenyl, alkynyl or an aromatic moiety of 1 or more carbon atoms that may be substituted with an oxygen, nitrogen or sulfur and X1 and X2 are independently selected to be moiety that is susceptible to hydrogen bonding and processing the tissue or cellular sample. A reagent used in the processing of a tissue or cellular sample with the reagent containing an evaporation reducing agent.
Thu, 03 Nov 2016 08:00:00 EDTMethods are provided for nucleic acid analysis. In an illustrative method, allele amplification bias is used to amplify preferentially a target nucleic acid that is present in a low allele fraction.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides a new and improved oligonucleotide detection method based on the nanopore technology with a probe containing a complementary sequence to the target oligonucleotide and a terminal extension at the probe's 3′ terminus, 5′ terminus, or both termini. The improved nanopore sensor with the probe enables sensitive, selective, and direct detection, differentiation and quantification of target oligonucleotides such as miRNAs. The inventive detection method may also be employed as a non-invasive and cost-effective diagnostic method for cancer detection based on miRNA levels in the patient's blood sample.
Thu, 03 Nov 2016 08:00:00 EDTProvided herein is a microplate for polymerase chain reaction (PCR), comprising a substrate formed of a material that is susceptible to heating PCR samples upon the application of an electromagnetic field and/or electromagnetic energy to said substrate. The substrate provides a PCR ramp rate of at least 5° C./second upon the application of an electromagnetic field and/or electromagnetic energy to said substrate.
Thu, 03 Nov 2016 08:00:00 EDTUse of at least one chromogenic and/or fluorogenic carboxylesterase and/or triacylglycerol-lipase substrate, to detect bacteria of the Bacillus cereus group in a sample capable of containing them.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides a swatch comprising a fabric and a colored lipid stain, wherein said colored lipid stain comprises one or more of several lipase substrates, at least one carotenoid, and optionally a color preserving agent. The present invention also provides a method for preparing the swatch.
Thu, 03 Nov 2016 08:00:00 EDTProvided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.
Thu, 03 Nov 2016 08:00:00 EDTHerein is reported a method for the recombinant production of a polypeptide in E. coli comprising the steps of i) cultivating an NADH dehydrogenase II-deficient E. coli expressing the polypeptide, and ii) recovering the polypeptide from the cell or the cultivation medium.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to the preparation of Tiacumicin B from a Dactylosporangium or Actinoplanes strain capable of producing Tiacumicin B utilizing spray drying and further extraction of the spray dried powder.
Thu, 03 Nov 2016 08:00:00 EDTThe object of the present invention is to provide a method for producing a hexenol glycoside by means of hexenol glycosyltransferase. The present invention provides a method for producing a hexenol glycoside by means of hexenol glycosyltransferase. The present invention provides a transformant transformed with a gene for hexenol glycosyltransferase and a method for preparing such a transformant.
Thu, 03 Nov 2016 08:00:00 EDT[Problem] To provide a production method capable of simply and efficiently producing a fructose-added carbohydrate using β-fructofuranosidase.[Solution]A method for producing a fructose-added carbohydrate, said method having a step in which a receptor substrate and a hydrate containing terminal fructose residue are brought into contact with: Escherichia coli expressing an anchor protein for expression on a cell surface and β-fructofuranosidase as one polypeptide,a composition including dead cells of the expressing Escherichia coli, ora polypeptide obtained from the expressing Escherichia coli and including an amino acid sequence of β-fructofuranosidase.
Thu, 03 Nov 2016 08:00:00 EDTA method for degrading or converting a cellulosic material is provided, comprising (a) subjecting the cellulosic material to an enzyme composition at a mild agitation with low rotation speed; and (b) subjecting the cellulosic material to an enzyme composition at a sufficient agitation with high rotation speed. A method for producing a fermentation product is further provided, comprising (a) saccharifying the cellulosic material with an enzyme composition at a mild agitation with low rotation speed; (b) saccharifying the cellulosic material with an enzyme composition at a sufficient agitation with high rotation speed; and (c) fermenting the hydrolyzed cellulosic material with one or more fermenting microorganisms to produce the fermentation product.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to host cells that produce compounds that are characterized as benzylisoquinolines, as well as select precursors and intermediates thereof. The host cells comprise one, two or more heterologous coding sequences wherein each of the heterologous coding sequences encodes an enzyme involved in the metabolic pathway of a benzylisoquinoline, or its precursors or intermediates from a starting compound. The invention also relates to methods of producing the benzylisoquinoline, as well as select precursors and intermediates thereof by culturing the host cells under culture conditions that promote expression of the enzymes that produce the benzylisoquinoline or precursors or intermediates thereof.
Thu, 03 Nov 2016 08:00:00 EDTThe invention provides non-naturally occurring microbial organisms comprising 1,4-butanediol (14-BDO) and gamma-butyrolactone (GBL) pathways comprising at least one exogenous nucleic acid encoding a 14-BDO and GBL pathway enzyme expressed in a sufficient amount to produce 14-BDO and GBL. The invention additionally provides methods of using such microbial organisms to produce 14-BDO and GBL.
Thu, 03 Nov 2016 08:00:00 EDTThe invention relates to a process for biochemical synthesis of 1,4-butanediamine in a microorganism having an increased level of an ornithine decarboxylase activity (increased ODC activity) as compared to the native level of the ornithine decarboxylase activity, wherein the increased ODC activity is obtained by means of overexpression of an ornithine decarboxylase encoding gene with increased translational and/or transcriptional efficiency, and wherein 1,4-butanediamine produced in the microorganism is excreted into a fermentation broth, and is recovered from the fermentation broth. In preferred embodiments also increased enzyme activity is obtained by of overexpression of either (i) an arginine decarboxylase encoding gene speA and an agmatinase encoding genespeB; or (ii) an arginine decarboxylase encoding gene speA and an agmatine iminohydrolase encoding gene aguA, and an N-carbamoylpotrescine amidohydrolase encoding geneaguB, and optionally also an agmatinase encoding gene speB. The invention also relates to vectors, plasmids and hosts carrying, at an increased level of activity, one or more of the enzyme activities as mentioned.
Thu, 03 Nov 2016 08:00:00 EDTThe present disclosure relates to a method for obtaining sugar and lignin fractions from lignocellulosic materials and to a method for producing fermentation products using the sugars obtained from the lignocellulose. The present disclosure also relates to a method for improving the sugar yield in the enzymatic hydrolysate by introducing a pre-treatment step of hydrothermal hydrolysis with a delignification step using a cationic compound.
Thu, 03 Nov 2016 08:00:00 EDTThis invention relates to improvements in the fermentation process used in the production of organic acids from biological feedstock using bacterial catalysts. The improvements in the fermentation process involve providing a fermentation medium comprising an appropriate form of inorganic carbon, an appropriate amount of aeration and a biocatalyst with an enhanced ability to uptake and assimilate the inorganic carbon into the organic acids. This invention also provides, as a part of an integrated fermentation facility, a novel process for producing a solid source of inorganic carbon by sequestering carbon released from the fermentation in an alkali solution.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to a recombinant microorganism for producing 1,3-propanediol, wherein a pathway converting pyruvate into 2,3-butanediol is inhibited in a microorganism having a pyruvate and acetyl CoA biosynthetic pathway. In addition, the present invention relates to a method for producing 1,3-propanediol by using the recombinant microorganism.
Thu, 03 Nov 2016 08:00:00 EDTKetol-acid reductoisomerase enzymes have been identified that provide high effectiveness in vivo as a step in an isobutanol biosynthetic pathway in bacteria and in yeast. These KARIs are members of a clade identified through molecular phylogenetic analysis called the SLSL Clade.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates, inter alia, to recombinant Gram-positive Clostridia host cells for producing solvents, fuels and/or chemical intermediates, and preferably ethanol, from plant cell walls comprising: (a) at least one nucleic acid encoding a plant cell wall degrading enzyme, wherein the host cells produce and secrete the plant cell wall degrading enzyme, (b) at least one nucleic acid encoding an enzyme that converts pyruvate to acetaldehyde and at least one nucleic acid encoding an enzyme that converts acetaldehyde to ethanol wherein the host cell is capable of expressing said nucleic acid, and, (c) a mutation in at least one nucleic acid encoding for an enzyme in a metabolic pathway which produces a metabolite other than acetaldehyde from pyruvate or ethanol from acetaldehyde, such that the mutation results in a reduced production of the metabolite.
Thu, 03 Nov 2016 08:00:00 EDTProvided herein is an isolated Methanothermobacter microorganism that is (a) a microorganism of Methanothermobacter thermautotrophicus strain UC 120910, deposited on Dec. 21, 2010, with the American Type Culture Collection (ATCC) under ATCC® Patent Deposit Designation No. PTA-11561, (b) a variant of the microorganism of Methanothermobacter thermautotrophicus strain UC 120910, or (c) a progeny of the microorganism of Methanothermobacter thermautotrophicus strain UC 120910, wherein the variant or progeny retains the phenotypic characteristics of the microorganism of Methanothermobacter thermautotrophicus strain UC 120910. Also provided herein is a substantially pure culture or monoculture comprising the Methanothermobacter microorganism of the disclosure. A system for converting electric power into methane, comprising a biological reactor having at least a cathode, an anode, a presently disclosed Methanothermobacter microorganism, water, and carbon dioxide, and method of using the system for converting electricity into methane are further provided herein.
Thu, 03 Nov 2016 08:00:00 EDTThe invention relates to methods for Rhizobia-mediated genetic transformation of plant cells, including soybean, canola, corn, and cotton cells. These include both VirD2-dependent and VirD2-independent methods. Bacterial species utilized include strains of Rhizobium sp., Sinorhizobium sp., and Mesorhizobium sp. Vectors for use in such transformation are also disclosed.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates in general to bacterial cells having a genetic alteration that results in increased expression of a protein of interest and methods of making and using such cells. Aspects of the present invention include Gram positive microorganisms, such as Bacillus species, having a genetic alteration that modifies activity of a protein encoded by the ykf operon and results in enhanced expression of a protein of interest.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to an isolated polypeptide comprising at least one intein or at least one intein fragment of said intein, wherein said intein is a naturally split intein with a N-terminal intein fragment split after 14-60 amino acids from the intein's N-terminal end and methods of using the same.
Thu, 03 Nov 2016 08:00:00 EDTMethods and constructs for the multiplex expression of highly active CRISPR guide RNAs (gRNAs) from RNA Polymerase II and III promoters, optionally in mammalian cells. The present invention is based, at least in part, on the discovery that Csy4, an endoribonuclease that recognizes a short RNA hairpin sequence, can be used to cleave out multiple functional gRNAs encoded on a single longer RNA transcript (produced from an RNA pol II or III promoter) in which the individual gRNAs are separated by Csy4 cleavage sites.
Thu, 03 Nov 2016 08:00:00 EDTDevices for separating materials from a host fluid are disclosed. The devices include a flow chamber, an ultrasonic transducer, and a reflector. The ultrasonic transducer and reflector create an angled acoustic standing wave oriented at an angle relative to the direction of mean flow through the flow chamber. The angled acoustic standing wave results in an acoustic radiation force having an axial force component that deflects the materials, so that the materials and the host fluid can thus be separated. The angled acoustic standing wave can be oriented at an angle of about 20° to about 70° relative to the direction of mean flow through the flow chamber to deflect, collect, differentiate, or fractionate the materials from the fluid flowing through the device at flow rates of about 400 mL/min up to about 700 mL/min.
Thu, 03 Nov 2016 08:00:00 EDTA method comprising (a) introducing a plurality of at least one phototrophic organism to a culture media to create a first mixture; (b) subjecting the first mixture to conditions suitable for growth of the phototrophic organism in the presence of a wavelength converting material to produce a concentrated mixture having a first cell titer; (c) diluting the concentrated mixture to produce a diluted mixture having a second cell titer; and (d) subjecting the diluted mixture to conditions suitable for growth of the phototrophic organism in the absence of the wavelength converting material.
Thu, 03 Nov 2016 08:00:00 EDTDescribed are compositions, in particular lyophilizates, containing proteolytic enzymes, and methods for producing the compositions. Typically these compositions contain one or more proteases with collagenase activity and a neutral protease, for example, thermolysin. The compositions are free of acetate salts. Surprisingly, such compositions can be dissolved in water more rapidly than lyophilized protease mixtures of the state of the art.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention.
Thu, 03 Nov 2016 08:00:00 EDTThe present disclosure relates to serine proteases cloned from Bacillus gibsonii, and variants thereof. Compositions containing the serine proteases are suitable for use in cleaning fabrics and hard surfaces, as well as in a variety of industrial applications.
Thu, 03 Nov 2016 08:00:00 EDTThe present specification discloses expression constructs comprising single-chain proteins comprising a di-chain loop region comprising an exogenous protease cleavage site and a protease that can cleave the exogenous protease cleavage site located within the di-chain loop, cell compositions comprising such expression construct, and intracellular methods of converting the single-chain protein into its di-chain form.
Thu, 03 Nov 2016 08:00:00 EDT[Problem] To provide an improved β-fructofuranosidase which enables the production of kestose with high efficiency while reducing the amount of a by-product such as nystose produced during the production of kestose. [Solution] An improved β-fructofuranosidase comprising an amino acid sequence which is produced by introducing an amino acid mutation into an amino acid sequence for a β-fructofuranosidase having 60% or higher identity to the amino acid sequence for wild-type β-fructofuranosidase which is represented by SEQ ID NO: 2, wherein the amino acid mutation is such a mutation that, when amino acid sequence alignment is performed, a histidine (H) residue corresponding to the position 395 as numbered from the N-terminal of the amino acid sequence for the wild-type β fructofuranosidase which is represented by SEQ ID NO: 2 can be replaced by an arginine (R) residue or a lysine (K) residue.
Thu, 03 Nov 2016 08:00:00 EDTThe present disclosure provides atomic structures of Cas9 with and without polynucleotides bound thereto. Also provided is a computer-readable medium comprising atomic coordinates for Cas9 polypeptides in both an unbound configuration and a configuration wherein the Cas9 polypeptide is bound to one or more polynucleotides. The present disclosure provides crystals comprising Cas9 polypeptides; and compositions comprising the crystals. The present disclosure provides methods for the engineering of Cas9 polypeptides wherein Cas9 activity has been altered, ablated, or preserved and amended with additional activities.
Thu, 03 Nov 2016 08:00:00 EDTMulti-domain recombinant proteins have a cutinase catalytic domain. The cutinase catalytic domain is a modular domain, which may be combined with other protein domains that also function in a modular fashion. For example, the cutinase catalytic domain can be operably linked to a polymer binding domain via a linker domain (e.g., a threonine/proline-rich linker polypeptide). The cutinase catalytic domain can be from an endogenous cutinase having a multi-domain modular organization, such as from the actinobacterium Kineococcus radiotolerans. The recombinant proteins are used in compositions, methods and uses, such as for use in industrial applications.
Thu, 03 Nov 2016 08:00:00 EDTDisclosed are mutant DNA polymerases having increased 3′-mismatch discrimination relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the mutant DNA polymerases.
Thu, 03 Nov 2016 08:00:00 EDTThe present disclosure relates to non-naturally occurring monooxygenase polypeptides useful for preparing prazole compounds, polynucleotides encoding the polypeptides, and methods of using the polypeptides.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to the production of hydroxylated protoilludenes and/or sesquiterpenoid protoilludene-type aryl esters using newly identified genes that can be employed. The present invention accordingly relates to a host microorganism that has been transformed with the newly identified nucleotide sequences and to methods employing the transformed microorganism.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to methods for the conversion of the substrate specificity of desaturases. Specifically, the present invention pertains to a method for the conversion of the substrate specificity of a Δ5 and/or Δ6 desaturase to the substrate specificity of a Δ4 desaturase, the method comprising: identifying regions and/or amino acid residues which control the substrate specificity of (i) the Δ5 and/or Δ6 desaturase and (ii) the Δ4 desaturase; and replacing in the amino acid sequence of the mentioned Δ5 and/or Δ6 desaturase, the regions and/or amino acid residues which control the substrate specificity of the Δ5 and/or Δ6 desaturase, by the corresponding regions and/or amino acid residues which control the substrate specificity of the Δ4 desaturase, thereby converting the substrate specificity of the Δ5 and/or Δ6 desaturase to the substrate specificity of the Δ4 desaturase. The present invention further concerns a method for the conversion of the substrate specificity of a Δ4 desaturase to the substrate specificity of a Δ5 and/or Δ6 desaturase, the method comprising: identifying regions and/or amino acid residues which control the substrate specificity of (i) the Δ4 desaturase and (ii) the Δ5 and/or Δ6 desaturase; and replacing in the amino acid sequence of the indicated Δ4 desaturase, the regions and/or amino acid residues which control the substrate specificity of the Δ4 desaturase, by the corresponding regions and/or amino acid residues which control the substrate specificity of the Δ5 and/or Δ6 desaturase, thereby converting the substrate specificity of the Δ4 desaturase to the substrate specificity of the Δ5 and/or Δ6 desaturase. In addition, the invention encompasses desaturases with converted substrate specificity.
Thu, 03 Nov 2016 08:00:00 EDTFructosyl amino acid oxidase is provided, which has an amino acid sequence as shown in SEQID. No. 1 or fructosyl amino acid oxidase having a homology of more than 80% with this amino acid sequence, on a corresponding site of an amino acid selected from following (a) to (f), having one or more amino acid residues conducting a substitution, obtained fructosyl amino acid oxidase having a higher thermostability: (a) 59-site glutamic acid, (b) 98-site glutamic acid, (c) 225-site glycine, (d) 277-site lysine, (e) 285-site glutamic acid, and (f) 355-site aspartic acid. The method for preparing the above oxidase and the test kit containing the enzyme for determining glycated albumin are also provided.
Thu, 03 Nov 2016 08:00:00 EDTThe present disclosure relates to engineered ketoreductase polypeptides for the preparation of hydroxyl substituted carbamate compounds, and polynucleotides, vectors, host cells, and methods of making and using the ketoreductase polypeptides.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides a flavin-binding glucose dehydrogenase that exhibits heat stability and has one or more amino acid substitutions at positions corresponding to positions 66, 68, 88, 158, 233, 385, 391 and 557 in the amino acid sequence set forth in SEQ ID NO: 1.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to a variant polypeptide having fumarate reductase activity, which has modified NADP(H)-dependent and/or NAD(H)-dependent activity as compared with a reference polypeptide having fumarate reductase activity. Such a variant may be overexpressed in a host cell in order to improve production of a dicarboxylic acid.
Thu, 03 Nov 2016 08:00:00 EDTDisclosed herein are compositions and methods for treating, ameliorating or preventing a retinal disease or condition; improving a photopic (day light) vision; for improving correcting visual acuity, improving macular function, improving a visual field, or improving scotopic (night) vision by administration of retinal progenitor cells. The subject matter described herein also provides cell populations comprising retinal progenitor cells and methods of isolation thereof.
Thu, 03 Nov 2016 08:00:00 EDTWell-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of maintaining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media. In addition, the present invention provides methods of differentiating ESCs or EBs formed therefrom for the generation of lineage specific cells.
Thu, 03 Nov 2016 08:00:00 EDTA method for culturing and maintaining a pluripotent stem cell in an undifferentiated state is provided. The method comprises culturing the pluripotent stem cell in a medium comprising an MEK inhibitor, a GSK3 inhibitor, a dual inhibitor of AMPK and/or BMP signaling and LIF. A cell produced by the method, cell culture medium and a kit for performing the method described is also provided.
Thu, 03 Nov 2016 08:00:00 EDTDescribed herein are cell culture media, kits and methods for preparing cell culture media, and methods for culturing cells, for example, cells of the female reproductive tract, and tumor cells.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides conjugates of DNA and cells by linking the DNA to a native functional group on the cell surface. The cells can be without cell walls or can have cell walls. The modified cells can be linked to a substrate surface and used in assay or bioreactors.
Thu, 03 Nov 2016 08:00:00 EDTA medium composition for increasing the colony number or colony size of microalgae includes, as an effective component, a conditioned medium derived from culture solution during the exponential phase of microalgae in culture. A solid medium contains the medium composition. A method for increasing the colony number or colony size of microalgae includes spreading and culturing microalgae on the solid medium.
Thu, 03 Nov 2016 08:00:00 EDTA culture device containing a culture vessel for culturing a cell, in which the culture device includes a thermostatic vessel having a stacker containing a plurality of culture vessels for culturing a cell, and an observation portion arranged to be isolated from an atmosphere at inside of the thermostatic vessel and having an object lens, an object lens drive portion, and a camera portion to observe a cell at inside of the culture vessel installed at an observation position at inside of the thermostatic vessel.
Thu, 03 Nov 2016 08:00:00 EDTA system for monitoring growth media within a controlled environment is provided and includes a well plate having a plate top and a plate side and defines at least one well cavity. The plate top includes a top opening and the plate side includes a side opening and the side opening is communicated with one of the at least one well cavity. The system includes a sensor assembly unit that includes a unit structure defining a reference material chamber containing a reference material, a sensor chamber having a chamber opening, and a base chamber. Additionally, the system includes a reference electrode communicated with the reference material and the base chamber. A media sensor is provided and is communicated with the chamber opening and a media sensor electrode communicated with the media sensor. The reference electrode and media sensor electrode are communicated with a processing device.
Thu, 03 Nov 2016 08:00:00 EDTContinuously Controlled Hollow fiber Bioreactor (CCHB) for the production of consistent quality cells or cell-derived products is provided. General components of the CCHB including a hollow fiber cell culture module, a new-medium chamber and a used-medium chamber, disposably attachable or detachable to the base devices such as rocking platform and circulation pumps. Quality of parameters including nutrient, oxygen, pH and temperature in the medium is optimally maintained during the production process. This ensures the controlled quality of the cell or cell-derived product throughout the process.
Thu, 03 Nov 2016 08:00:00 EDTAccording to the present invention, a problem of closed systems, namely minimizing the number of electromagnetic valves required to control a plurality of flow paths, can be addressed, and thus a low-cost cell culture device can be achieved. In this flow-path control method for X number of flow paths satisfying X≦2N, the X number of flow paths are selected by using N number of valves to simultaneously and selectively control the opening and closing of the plurality of flow paths.
Thu, 03 Nov 2016 08:00:00 EDTAccording to one embodiment, a measuring cell includes a main cell member, and a mixture supported by or held in the main cell member. The mixture includes a nonaqueous solvent-including medium and one or more enzyme bodies. The one or more enzyme bodies are selected from the group including an enzyme, a first composite including an enzyme and a molecular aggregate that includes a dispersant, a microcapsule including an enzyme-including core and a shell covering the core, a cell including an enzyme, a microorganism including an enzyme, and a second composite including an enzyme and a support immobilizing the enzyme.
Thu, 03 Nov 2016 08:00:00 EDTDisclosed is a wavelength conversion material for use in a photo-bioreactor for growing phototrophic organisms. The wavelength conversion material includes an organic fluorescent dye and a polymeric matrix, wherein the organic fluorescent dye is solubilized in the polymeric matrix. The wavelength-conversion material is capable of absorbing light comprising a wavelength of 280 to 650 nm and emitting the absorbed light at a wavelength of 400 to 800 nm.
Thu, 03 Nov 2016 08:00:00 EDTA cleaning composition comprising a nuclease enzyme, preferably a deoxyribonuclease and/or ribonuclease enzyme and a surfactant system comprising an anionic surfactant and a nonionic surfactant wherein the weight ratio of anionic to non-ionic surfactant is from 1.5:1 to 1:10.
Thu, 03 Nov 2016 08:00:00 EDTA method of treating a textile in which the fabric is contacted with a cleaning composition comprising from 5 to 80% by weight anionic surfactant and a nuclease enzyme; optionally friction is applied to rub said cleaning composition into the fabric surface. In an optional third step, the fabric is then contacted with an aqueous liquor, optionally comprising cleaning and/or treatment composition, in a subsequent wash or rinse step.
Thu, 03 Nov 2016 08:00:00 EDTMethod for treating a hydrophobically-modified textile with an aqueous solution of a nuclease enzyme, preferably a deoxyribonuclease or ribonuclease enzyme, rinsing and drying the textile. Use of the finishing step for improved cleaning with an aqueous solution of a nuclease enzyme, preferably a deoxyribonuclease or ribonuclease enzyme
Thu, 03 Nov 2016 08:00:00 EDTA method of treating a textile in which a textile is contacted with an aqueous solution comprising a nuclease enzyme, preferably a deoxyribonuclease or ribonuclease enzyme and low levels of alkyl benzene sulphonate surfactant, and optionally rinsing and drying the textile.
Thu, 03 Nov 2016 08:00:00 EDTA method of treating a fabric, comprising contacting the fabric with an aqueous liquor comprising a fabric care component selected from the group consisting of cationic softening-compounds, silicone softening-compounds, paraffins, dispersible polyolefins, waxes and mixtures thereof; and contacting the fabric with an aqueous liquor comprising a nuclease enzyme, preferably a deoxyribonuclease or ribonuclease enzyme. The aqueous liquor may be provided by adding a cleaning or treatment composition to water. Preferably the composition comprises a surfactant, the wash liquor comprising from 0.05 to 4 g/l of a surfactant.
Thu, 03 Nov 2016 08:00:00 EDTDisclosed herein are processes for obtaining a microbial oil comprising one or more polyunsaturated fatty acids (PUFAs) from one or more microbial cells by lysing the cells to form a lysed cell composition, treating the lysed cell composition to form an oil-containing emulsion and then recovering the oil from the oil-containing emulsion. Further disclosed herein is microbial oil comprising one or more PUFAs that is recovered from microbial cells by at least one process described herein.
Thu, 03 Nov 2016 08:00:00 EDTDisclosed herein are processes for obtaining a microbial oil comprising one or more polyunsaturated fatty acids (PUFAs) from one or more microbial cells by lysing the cells to form a lysed cell composition and then recovering the oil from the lysed cell composition. Further disclosed herein is microbial oil comprising one or more PUFAs that is recovered from microbial cells by at least one process described herein.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser9lPhe substitution in the hA19 VH sequence.
Thu, 03 Nov 2016 08:00:00 EDTAn anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
Thu, 03 Nov 2016 08:00:00 EDTUses of the protein cereblon as a predictor of clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.